Hepatic encephalopathy
Drug research and approvals for hepatic encephalopathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 22 studies of hepatic encephalopathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 1 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 22
- Trials authorized in Canada: 6
- FDA orphan approvals: 1
- EU medicines: 0
Recruiting Now
Newest start dates first, of 22 recruiting on ClinicalTrials.gov ↗- Pre-emptive RTO for An Early Detected Gastric Varices in CT/MR Angiogram TrialNCT07168395 · Not applicable · University of California, Los Angeles · starts Oct 1, 2026
- Coil-Assisted Small-Diameter Covered-Stent Shunt Reduction for Refractory Hepatic Encephalopathy After TIPSNCT07799948 · Not applicable · Air Force Military Medical University, China · starts Sep 1, 2026
- 4D-Flow MRI Assessment of Portal Hypertension and TIPS Outcomes in CirrhosisNCT07554183 · Not applicable · Assistance Publique - Hôpitaux de Paris · starts Aug 25, 2026
- Fecal Microbiota Transplantation for the Treatment of Refractory Hepatic Encephalopathy After TIPS SurgeryNCT07683936 · Early Phase 1 · Air Force Military Medical University, China · starts Jun 1, 2026
- Apixaban-PK Trial: Preventing Portal Hypertension Complications in CirrhosisNCT07521332 · Phase 4 · Asian Institute Of Medical Sciences · starts Apr 1, 2026
- Development of a Cognitive Tool for Rapid and Reliable Screening of Minimal Hepatic Encephalopathy: Pilot StudyNCT06619106 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Jan 29, 2026
- The Liver Cirrhosis Cognitive Decline Scale (LiCCoS)NCT07418008 · Not reported · University of Malaya · starts Dec 15, 2025
- Comparison of Underdilated Versus Standard TIPS in Preventing Variceal Rebleeding in Patients With CirrhosisNCT07253389 · Not applicable · Air Force Military Medical University, China · starts Oct 20, 2025
- Affect of Melatonin on Sleep and Cognition in CirrhosisNCT07046429 · Not applicable · Weill Medical College of Cornell University · starts Aug 5, 2025
- Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)NCT06483737 · Not applicable · General Hospital of Shenyang Military Region · starts Jun 24, 2025
Trials Authorized in Canada
Newest first; search them all in Canada trials| Mar 7, 2022 | A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin soluble solid dispersion (ssd) tablets for the…RIFAXIMIN | Bausch Health | Closed |
| Dec 21, 2021 | A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin soluble solid dispersion (ssd) tablets for the…RIFAXIMIN | Bausch Health | Ongoing |
| Dec 24, 2015 | A prospective open label single centre trial of rbx2660 (microbiota suspension) in the management of hepatic encephalopathy (he)RBX2660 (MICROBIOTA SUSPENSION) | GOVERNORS OF THE UNIVERSITY OF ALBERTA | Ongoing |
| Apr 23, 2014 | A prospective, open label, single center trial of fecal microbiota transplantation (fmt) in the management of hepatic encephalopathyFECAL MICROBIOTA TRANSPLANTATION | GOVERNORS OF THE UNIVERSITY OF ALBERTA | Closed |
| Dec 19, 2013 | Multicenter, randomized phase 2b study to evaluate the efficacy, safety and tolerability of ocr-002 (ornithine phenylacetate) in hospitalized patients with…OCR-002 | OCERA THERAPEUTICS INC | Ongoing |
| Aug 15, 2013 | "human biotherapy in the management of hepatic encephalopathy"HUMAN BIOTHERAPY | GOVERNORS OF THE UNIVERSITY OF ALBERTA | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Mar 24, 2010 | XifaxanReduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age | Salix Pharmaceuticals, Inc. | Approved |
| Apr 7, 2010 | L-ornithine phenylacetateTreatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disase | Amalive Limited | Designated |
| Jun 3, 2005 | Sodium phenylacetate/sodium benzoate 10%/10% InjectionTreatment of grade III and IV hepatic encephalopathy | Ucyclyd Pharma, Inc. | Designated |
| Mar 4, 2005 | Sodium aluminosilicateTreatment of chronic hepatic encephalopathy | Westhaven Therapeutics Corporation | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA